On September 16, 2022, Mr. Mulacek purchased 47,376 shares of Common Stock at $11.9157 weighted average price per share in the open market using personal funds.
On September 19, 2022, Mr. Mulacek purchased 90,759 shares of Common Stock at $11.7834 weighted average price per share in the open market using personal funds.
On September 20, 2022, Mr. Mulacek purchased 100 shares of Common Stock at $12.00 per share in the open market using personal funds.
On October 11, 2022, as compensation for serving on the Board, the Board granted to Mr. Mulacek under the Company’s 2022 Stock and Incentive Compensation Plan (the “2022 Plan”) restricted stock units for 7,500 shares of Common Stock, which vest 13 months after the date of the grant. The restricted stock units vested in full in November 2023 and the 7,500 shares were issued to Mr. Mulacek.
On December 19, 2022, Mr. Mulacek purchased 94,707 shares of Common Stock at $9.95 per share in the open market using personal funds.
On December 30, 2022, as compensation for serving on the Board, the Board granted to Mr. Mulacek under the 2022 Plan restricted stock units for 7,500 shares of Common Stock, which vest 13 months after the date of the grant. The restricted stock units vested in full in January 2024 and the 7,500 shares were issued to Mr. Mulacek.
On May 30, 2023, Mr. Mulacek purchased 5,153 shares of Common Stock at $8.83 weighted average price per share in the open market using personal funds.
On May 31, 2023, Mr. Mulacek purchased 20,377 shares of Common Stock at $8.99 weighted average price per share in the open market using personal funds.
On June 8, 2023, as compensation for serving on the Board, the Board granted to Mr. Mulacek under the 2022 Plan (i) restricted stock units for 10,000 shares of Common Stock, which vest 13 months after the date of the grant and (ii) a non-qualified stock option to purchase 40,000 shares of Common Stock at an exercise price of $11.83 per share. The option expires on June 8, 2028 and vests in four equal quarterly installments beginning on September 8, 2023.
On September 19, 2023, Mr. Mulacek made a bridge loan to Empire North Dakota LLC, a Delaware limited liability company (“Empire North Dakota”) and a wholly owned subsidiary of the Company, in the amount of $5.0 million with a maturity date of October 31, 2023 (the “Bridge Loan”). On October 31, 2023, Mr. Mulacek entered into an amendment to the Bridge Loan with Empire North Dakota for the sole purpose of extending the maturity date of the Bridge Loan from October 31, 2023 to November 9, 2023. On November 9, 2023, Mr. Mulacek amended and restated the Bridge Loan with Empire North Dakota (the “Amended and Restated Bridge Loan”) for the purpose of, among other things: (a) extending the maturity date of the Bridge Loan from November 9, 2023 to December 31, 2024; and (b) providing that interest payments will be paid in shares of Common Stock instead of cash on each of the following dates (or if any such date is not a business day, the next following business day), except upon the occurrence of an Event of Default (as defined in the Amended and Restated Bridge Loan), in which case interest will accrue and be paid in cash on demand: (i) November 16, 2023; (ii) December 31, 2023; (iii) March 31, 2024; (iv) June 30, 2024; (v) September 30, 2024; and (v) December 31, 2024.
On November 29, 2023, the Company entered into a Securities Purchase Agreement with Mr. Mulacek, which Agreement was amended on December 1, 2023, pursuant to which Mr. Mulacek purchased from the Company (a) 609,013 shares of Common Stock for an aggregate purchase price of $5,000,000 (or $8.21 per share) in cash and (b) 631,832 shares of Common Stock for an aggregate
CUSIP NO. 292034 30 3 | 13D | Page 7 of 9 pages |
purchase price of $5,054,657.53 (or $8.00 per share) which was paid through cancellation and extinguishment of the outstanding principal amount and all accrued interest thereon under the Amended and Restated Bridge Loan (the “Securities Purchase Agreement”). Mr. Mulacek used his personal funds for the purchase of the shares described in this paragraph that were purchased with cash. The Securities Purchase Agreement also contains certain covenants, representations and warranties, and other customary terms and conditions, including the Company using its commercially reasonable best efforts to register the resale of the shares of Common Stock of the Company acquired under the Securities Purchase Agreement under the Securities Act of 1933, as amended, by February 15, 2024.
On March 7, 2024, the Company initiated a rights offering to holders of Common Stock, as described in the Company’s prospectus supplement dated March 7, 2024, as supplemented by the Company’s prospectus supplement dated March 28, 2024 (the “Rights Offering”). Pursuant to the Rights Offering, each holder of Common Stock of record as of March 7, 2024 received at no charge one right for each share of Common Stock, and each right carried with it a basic subscription right, which entitled the holder to purchase 0.161 of a share of Common Stock, and an over-subscription right, which entitled holders that exercised their basic subscription rights in full to subscribe for additional shares of Common Stock that were not purchased by other stockholders pursuant to their basic subscription rights, subject to proration. The subscription rights had a subscription price of $5.00 per whole share of Common Stock.
The Rights Offering expired at 5:00 p.m., Eastern Time, on April 10, 2024 and was fully subscribed. On April 22, 2024, pursuant to the exercise in full of subscription rights, including over-subscription rights, (a) Mr. Mulacek purchased 918,461 shares of Common Stock for an aggregate subscription price of $4,592,305; (b) PIE purchased 109,836 shares of Common Stock for an aggregate subscription price of $549,180; (c) Big Red Revocable Trust purchased 97,994 shares of Common Stock for an aggregate subscription price of $489,970 (d) Five Sterling LP purchased 89,516 shares of Common Stock for an aggregate subscription price of $447,580; and (e) Mr. Mulacek’s spouse purchased 7,937 shares of Common Stock for an aggregate subscription price of $39,685. The subscription prices were funded using Mr. Mulacek’s personal funds.
ITEM 4. PURPOSE OF TRANSACTION
Mr. Mulacek acquired and owns or owned the shares of Common Stock, convertible notes, warrants to purchase Common Stock, stock options and restricted stock units, as described herein, for investment purposes. Mr. Mulacek is a director of the Company and serves as Chairman of the Board. Mr. Mulacek expects that he will continue to receive equity awards as compensation for serving on the Board. Mr. Mulacek may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Company, dispose of any such securities, or engage in discussions with the Company concerning such acquisitions or dispositions or further investments in the Company. Mr. Mulacek intends to review his investment in the Company from time to time and, depending upon his assessment of pertinent factors, including without limitation, the price and availability of shares of Common Stock or other securities of the Company, subsequent developments affecting the Company, the Company’s business and prospects, other investment and business opportunities available to him, general stock market and economic and industry conditions and tax and estate planning considerations, may decide at any time to increase or to decrease the size of his investment in the Company in the open market, in privately negotiated transactions, pursuant to Rule 10b5-1 trading plans or otherwise.
On March 8, 2022, the Company formalized the issuance of preferred stock as was required under the terms of the Company’s May 2021 financing agreements with EEF and issued six shares of Series A Voting Preferred Stock to Mr. Mulacek, one of the principals of EEF, as EEF’s designee. The Series A Voting Preferred Stock was issued in connection with the strategic investment in the Company by EEF. The Series A Voting Preferred Stock is not convertible into the Common Stock or any other security of
CUSIP NO. 292034 30 3 | 13D | Page 8 of 9 pages |
the Company. For so long as the Series A Voting Preferred Stock is outstanding, the Board will consist of six directors. Three of the directors are designated as the Series A Directors and the three other directors (each, a “common director”) are elected by the holders of Common Stock and/or any Preferred Stock of the Company (other than the Series A Voting Preferred Stock) granted the right to vote on the common directors. The holders of the Series A Voting Preferred Stock have the exclusive right, voting separately and as a single class, to vote on the election, removal and/or replacement of the Series A Directors. Holders of Common Stock or other Preferred Stock of the Company have no right to vote on the Series A Directors. The approval of the holders of the Series A Voting Preferred Stock, voting separately and as a single class, is required to authorize any resolution or other action to issue or modify the number, voting rights or any other rights, privileges, benefits or characteristics of the Series A Voting Preferred Stock, including without limitation, any action to modify the number, structure and/or composition of the Board. Mr. Mulacek serves as a Series A Director of the Company. In the case of any tie vote or deadlock of the Board, Mr. Mulacek currently has the deciding, tiebreaking vote.
Except as described in this Schedule 13D, Mr. Mulacek does not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of Schedule 13D, although Mr. Mulacek, at any time and from time to time, may review, reconsider and change his position and/or change his purpose and/or develop such plans or proposals.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) | | Mr. Mulacek is the beneficial owner of 6,192,432 shares of Common Stock, which includes (i) 40,000 shares issuable upon the exercise of stock options that are currently exercisable and (ii) 10,000 shares underlying restricted stock units that vest within 60 days of the date of this Schedule 13D, or 19.8% of the total issued and outstanding shares of Common Stock. |
| | |
| | The ownership percentage included in this Schedule 13D for Mr. Mulacek is based on 31,221,006 outstanding shares of Common Stock as of June 17, 2024, which figure was provided by the Company. In accordance with the rules of the SEC, the 50,000 shares that Mr. Mulacek is deemed to beneficially own by virtue of having a right to acquire upon exercise of the stock options and vesting of the restricted stock units are considered outstanding (and thus added to the above outstanding share number) solely for purposes of calculating his percentage of ownership. |
| | |
(b) | | The responses of Mr. Mulacek to Items 7-11 of the cover page of this Schedule 13D are incorporated herein by reference. |
| | |
(c) | | The responses to Item 3 of this Schedule 13D are incorporated herein by reference. |
| | |
(d) | | Not applicable. |
| | |
(e) | | Not applicable. |
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
Not applicable.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
Not applicable.
CUSIP NO. 292034 30 3 | 13D | Page 9 of 9 pages |
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| |
| |
Date: June 28, 2024 | /s/ Phil E. Mulacek |
| Phil E. Mulacek |